Actively Recruiting
Drug Effects on Mood and Behavior - Expectancy
Led by University of Chicago · Updated on 2026-05-04
48
Participants Needed
1
Research Sites
49 weeks
Total Duration
On this page
Sponsors
U
University of Chicago
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study will examine the effects of a single low dose of the 5HT2A agonist LSD (Lysergic Acid Diethylamide) (13 µg) or placebo in individuals who are or are not explicitly told what drug they will receive. Although it is known that expectancies strongly influence subjective responses to most drugs, no studies have examined expectancies on response to a very low dose of LSD. This is especially important in the context of 'microdosing' of drugs. People who practice microdosing typically do so with strong expectations of positive effects, making it difficult to determine whether there is a pharmacological effect. To minimize expectancies in the laboratory, participants are usually not told exactly what drug they will receive (i.e., double-blind), but given a range of possibilities. In the present study, the study team will test half the subjects under single-blind conditions, where the participants (but not the research assistant) will know exactly what they are receiving. Other subjects will receive the usual instructions. Healthy volunteers will receive either a marginally detectable dose of LSD (13 micrograms) or placebo, under conditions where they i) know for sure what drug they are receiving or ii) where the identity of the drug is uncertain. Four groups of subjects (N=12 each) will attend single 4-hour laboratory session. The study team will examine subjective and behavioral responses to the drug in each of four conditions (Known-Drug; Known-Placebo; Uncertain-Drug; Uncertain-Placebo).
CONDITIONS
Official Title
Drug Effects on Mood and Behavior - Expectancy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- English fluency
- High school education or higher
- Body mass index (BMI) between 19 and 30 kg/m2
You will not qualify if you...
- Medical conditions that contraindicate participation, such as liver disease, abnormal EKG, or cardiovascular disease as determined by the study physician
- High blood pressure greater than 140/90
- Current suicidal thoughts or suicide attempt within the past 12 months
- Severe substance use disorder in the past year
- Personal or first-degree family history of psychosis
- Current use of any psychiatric medication (must have stopped conventional antidepressants at least 2 weeks prior)
- Active panic disorder
- Severe obsessive-compulsive disorder
- Severe post-traumatic stress disorder
- Women who are pregnant or planning to become pregnant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Chicago
Chicago, Illinois, United States, 60637
Actively Recruiting
Research Team
H
Hanna Molla
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here